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Abstract
Background: Hemophilia B is an X‐linked recessive disorder caused by muta-
tions in the F9 on Xq27.1. Mainly males are affected but about 20% of female
carriers have clotting factor IX activity below 0.40 IU/ml and bleeding problems.
Fragile‐X syndrome (FMR1) and FRAXE syndrome (AFF2) are well‐known
causes of X‐linked recessive intellectual disability. Simultaneous deletion of both
FMR1 and AFF2 in males results in severe intellectual disability. In females the
phenotype is more variable. We report a 19‐year‐old female with severe intellec-
tual disability and a long‐standing bleeding history.
Methods: A SNP array analysis (Illumina Human Cyto 12‐SNP genotyping
array) and sequencing of F9 were performed. Laboratory tests were performed to
evaluate the bleeding diathesis.
Results: Our patient was diagnosed with mild hemophilia B after finding an 11
Mb deletion of Xq26.3q28 that included the following genes among others IDS,
SOX3, FMR1, AFF2, and F9.
Conclusion: The case history demonstrates that a severe bleeding tendency sug-
gestive of a hemostasis defect in patients with intellectual disability warrants care-
ful hematological and genetic work‐up even in the absence of a positive family
history.
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1 | INTRODUCTION
Hemophilia B is an X‐linked recessive bleeding disorder
caused by mutations in the F9 (OMIM 300746) on Xq27.1
resulting in reduced factor IX (FIX) activity. It occurs in
about 2.8 cases per 100.000 males (Berntorp & Shapiro,
2012). Patients may experience surgery or trauma‐induced
bleeding and, if more severe, spontaneous bleedings, for
which they can be treated prophylactically or on‐demand
with FIX concentrate. Although mainly males are affected,
about 20% of female carriers have FIX activity below
0.40 IU/ml (Konkle, Josephson, & Nakaya Fletcher, 1993),
which is thought to be caused by skewed X‐inactivation.
Mutations in the F9 occur de novo in up to half of the
families. Point mutations are the most frequent cause of
hemophilia B, deletions and duplications account for only*These authors contributed equally and share first authorship.
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3% (Li, Miller, Payne, & Craig Hooper, 2013). Approxi-
mately 30% of affected males have no family history of
hemophilia B (Sommer, Scaringe, & Hill, 2001). Here, we
report a 19‐year‐old female with severe intellectual disabil-
ity (ID) and a long‐standing bleeding history, who was
diagnosed with mild hemophilia B after finding a large
Xq‐deletion that included the F9.
1.1 | Ethical compliance
This case study was not subject to the Medical Research
Involving Human Subjects Act (WMO) as it only involved
file research and no additional diagnostic tests were per-
formed. Informed consent of the legal representatives of
our patient was obtained.
2 | METHODS AND RESULTS
The patient was the third child of healthy unrelated parents
and had two healthy sisters. There was no bleeding disor-
der known in the family. She was born at 41 weeks after
spontaneous delivery, weighing 3,450 g (50th percentile).
Apgar scores were 10 and 10 at 1 and 5 min, respectively.
After birth she was hypotonic and had feeding difficulties.
She had severe developmental delay already apparent dur-
ing infancy, severely impaired speech development, and
did not walk until the age of 10 years. Her past medical
history was remarkable because of a long‐standing history
of easy bruising and several severe bleeding episodes. At
age 2 she fell from a chair and developed a large head
wound. Ten days after initial healing, a rebleeding
occurred. At 12 years she fell off the stairs and developed
a severe perineal bleed for which she was admitted to the
hospital in hypovolemic shock. She received multiple blood
transfusions and rebleeding occurred twice with 1‐week
interval. She also had a tooth extraction and another head
trauma with prolonged bleeding. Occasionally she had
large hematomas mostly on the abdomen. No muscle or
joint bleeds occurred. No detailed investigation for a bleed-
ing disorder was performed.
At 19 years of age she was seen at the department of
clinical genetics (Figure 1). She had a length of 158 cm
(−1.8 SD) and a head circumference of 54.6 cm (−0.5
SD). She was obese with a good appetite and lack of sati-
ety especially during childhood. Clinical examination
revealed abnormal fat distribution mainly localized on the
abdomen, thighs and buttocks. She had deep set eyes,
periorbital fullness, mild upslanting eyelids, a prominent
chin, large ears, small hands 15.7 cm (−3 SD), slight
tapering of the fingers, soft skin of the hands, joint hyper-
laxity of the hands and small feet (Figure 1). On neurolog-
ical examination she was severely hypotonic, had a
stumbling gait and dysarthria. She communicated using
few words and gestures. She has intermittent exotropia.
Also, she still has urinary and fecal incontinence. She has
primary amenorrhea but normal secondary sex characteris-
tics, without signs of premature ovarian failure (POF) on
endocrinological evaluation (LH 4.8 U/L; FSH 4.9 U/L;
estrogen 93 pmol/L).
At 2 years of age, chromosome analysis showed a nor-
mal female karyotype. Metabolic blood‐ and urine analyses,
including sialotransferrines, were normal. DNA analyses
for Prader‐Willi‐ and Fragile‐X‐syndrome were both nega-
tive. An MRI of the brain at the age of 3 showed a thin
corpus callosum at the splenium, but no other structural
abnormalities. Recently, SNP array analysis (Illumina
Human Cyto 12‐SNP genotyping array) was performed
which showed an 11 Mb interstitial deletion of the chromo-
somal region Xq26.3q28 [arr Xq26.3q28(137,097,172–
148,991,868)]. The region contains 118 annotated genes
(Figure 2). The OMIM disease‐associated genes located in
this region are IDS (OMIM 300823), SOX3 (OMIM
313430), FMR1 (OMIM 309550), AFF2 (OMIM 300806),
and F9 (Figure 2). The Xq26.3q28 deletion was either de
novo or due to (germline) mosaicism in one of the parents.
FISH analysis in both the patient and her parents did not
reveal structural X‐chromosome abnormalities.
Because of the bleeding diathesis and potential FIX
defect based on the F9 deletion, the patient was referred by
the clinical geneticist to the hemophilia treatment center.
Laboratory results were normal for PFA, VWF:Ag, VWF:
CB, VWF:Act, and PT. FIX was 0.20 IU/ml (normal value:
0.60–1.40 IU/ml). Surprisingly, there was a normal APTT
(29 s, normal value 22–32 s), most likely due to a FVIII of
1.59 IU/ml (normal value: 0.60–1.40 IU/ml).
She scored a 5 on the ISTH (International Society on
Thrombosis and Hemostasis) Bleeding Assessment Tool.
Based on her history and the laboratory results she was
diagnosed as a hemophilia B carrier due to a F9 deletion.
To exclude the presence of a second mutation on the
other F9‐allele contributing to the phenotype, we per-
formed sequence analysis of F9. This did not reveal any
additional mutations. In rare cases moderate to severe
hemophilia B has been seen in females and this has gener-
ally been ascribed to skewed X‐inactivation. To test for
skewed X‐inactivation we analyzed urine for the presence
of abnormal mucopolysaccharide patterns indicative of
decreased IDS activity in Hunter syndrome (mucopolysac-
charidosis type 2, MPS2). Additionally, we performed pitu-
itary function evaluation (thyroid axis, growth hormone
axis, and prolactin) and tested X‐inactivation in peripheral
blood leukocytes using the analysis of the methylation sta-
tus of the AR locus located in Xq12 (Allen, Zoghbi, Mose-
ley, Rosenblatt, & Belmont, 1992). No evidence for MPS2,
pituitary dysfunction or skewed X‐inactivation was found.
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3 | DISCUSSION
We report a 19‐year‐old female with severe intellectual dis-
ability (ID) and a long‐standing bleeding history, who was
diagnosed with mild hemophilia B after finding a large
Xq‐deletion that included the F9. This demonstrates that a
severe bleeding tendency suggestive of a hemostasis defect
in patients with intellectual disability warrants careful
hematological and genetic work‐up even in the absence of
a positive family history. F9 deletions can range from a
few base pairs to several megabases and are found in
approximately 3% of patients with hemophilia B. In our
patient the hemizygous state of F9 likely caused mild
hemophilia B as is well known in carriers of hemophilia
(Nisen & Waber, 1989). In accordance with a previous
study, we could not demonstrate skewed X‐inactivation
(Orstavik, Scheibel, Ingerslev, & Schwartz, 2000). The
inability to consistently demonstrate skewed X‐inactivation
in hemophilia B carriers most likely reflects the usage of
blood for these studies. A more reliable way to study the
role of the X‐inactivation pattern in hemophilia B carriers
would be to directly examine liver tissue, which is non‐
ethical. Although skewed X‐inactivation is the most impor-
tant hypothesis to explain variability in FIX activity in car-
riers, it cannot be excluded that other factors (including
genetic) influence factor IX activity in carriers.
Several large deletions of the Xq26‐q28 region have been
reported that partly overlap with our patient's deletion. The
other OMIM disease‐associated genes located in the deletion
found in our patient include IDS (mucopolysaccharidosis
type 2, MPS2) (Johnson, van Diggelen, Dajnoki, & Boda-
mer, 2013), SOX3 (related to pituitary development) (Rizzoti
(a) (b)
FIGURE 1 Pictures of the patient. (a)
Notice deep set eyes, periorbital fullness,
wide nasal root, thin upper vermilion
border, and prominent chin. (b) Notice
small hands with smooth skin and slight
tapering of the fingers
FIGURE 2 Schematic representation of X‐chromosome and genes in the Xq26‐q28 region. Region of deletion in our patient is highlighted
by the red box. The OMIM disease‐associated genes in green and all UCSC annotated genes in blue within the deletion region (hg19) are shown.
Image was adapted from http://genome.ucsc.edu/cgi-bin/hgTracks
STOOF ET AL. | 3
et al., 2004), FMR1 (Fragile‐X syndrome), and AFF2
(FRAXE syndrome) (Cordts, Christofolini, Dos Santos,
Bianco, & Barbosa, 2011; Moore et al., 1999). A unique fea-
ture in our patient was that in addition to the genes FMR1,
AFF2, and IDS, F9 was deleted. Hemizygosity for IDS has
rarely been shown to result in MPS2 in females (Clarke et
al., 1992). In our patient no evidence for MPS2 was found.
Duplications of the SOX3 and polyalanine tract expansions
of the C‐terminal domain of SOX3 have been linked to
septo‐optic dysplasia, ID, and panhypopituitarism. In accor-
dance with a previous publication reporting SOX3 deletion,
we found no evidence for pituitary dysfunction or visual
problems (Helle et al., 2013). A more recent paper suggested
that the deletion of SOX3 may even be causative of mild
intellectual disability (Jourdy et al., 2016). Deletion of
FMR1 and AFF2 has been shown to cause fragile X syn-
drome and probably FRAXE‐syndrome (Coffee et al., 2008;
Sahoo et al., 2011). Simultaneous deletion of both FMR1
and AFF2 in males results in severe ID and variable other
features including hypotonia, epilepsy, obesity, and autism
(Coffee et al., 2008). In females the phenotype is more vari-
able: some had ID, obesity, and primary amenorrhea,
whereas others had primary amenorrhea or POF without ID
(Coffee et al., 2008; Mercer et al., 2013). The variability of
the phenotype in females may be related to differences in X‐
inactivation patterns. This is supported by the finding that
within families there may be marked variability in the grade
of intellectual ability and age of onset of POF (Fimiani et al.,
2006; Mercer et al., 2013). It remains unclear why deletion
of the Xq26.3q28 region is involved with POF. One theory
is that FMR1 is involved, because premutations in FMR1 are
associated with POF. It is unclear whether deletion of FMR1
has a similar effect. An alternative explanation is that other
genes within the Xq26.3q28 region are involved.
The case history demonstrates that a severe bleeding
tendency suggestive of a hemostasis defect in patients with
intellectual disability warrants careful hematological and
genetic work‐up even in the absence of a positive family
history. Especially, since numerous genetic conditions are
characterized by both intellectual disability and increased
bleeding tendency and a bleeding disorder may be recog-
nized less easily in people with intellectual disability (as is
the case for many medical conditions).
ACKNOWLEDGMENTS
The authors thank the patient and her family for granting
us permission to share her story and pictures within this
publication.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
AUTHOR CONTRIBUTION
RK, FWGL, and JAK clinically reviewed the patient and
wrote the manuscript. SCMS performed research and wrote
the manuscript. FATV performed analyses and critically
revised the manuscript. MJHAK interpreted the data and
critically revised the manuscript. All authors approved the
final version of the manuscript.
PATIENT CONSENT
Informed consent of the parents was obtained.
ORCID
Rogier Kersseboom http://orcid.org/0000-0002-7824-
8941
REFERENCES
Allen, R. C., Zoghbi, H. Y., Moseley, A. B., Rosenblatt, H. M., &
Belmont, J. W. (1992). Methylation of HpaII and HhaI sites near
the polymorphic CAG repeat in the human androgen‐receptor
gene correlates with X chromosome inactivation. American Jour-
nal of Human Genetics, 51, 1229–1239.
Berntorp, E., & Shapiro, A. D. (2012). Modern haemophilia care.
Lancet, 379, 1447–1456. https://doi.org/10.1016/S0140-6736(11)
61139-2
Clarke, J. T., Wilson, P. J., Morris, C. P., Hopwood, J. J., Richards,
R. I., Sutherland, G. R., & Ray, P. N. (1992). Characterization of
a deletion at Xq27‐q28 associated with unbalanced inactivation of
the nonmutant X chromosome. American Journal of Human
Genetics, 51, 316–322.
Coffee, B., Ikeda, M., Budimirovic, D. B., Hjelm, L. N., Kaufmann,
W. E., & Warren, S. T. (2008). Mosaic FMR1 deletion causes
fragile X syndrome and can lead to molecular misdiagnosis: A
case report and review of the literature. American Journal of Med-
ical Genetics. Part A, 146A, 1358–1367. https://doi.org/10.1002/
(ISSN)1552-4833
Cordts, E. B., Christofolini, D. M., Dos Santos, A. A., Bianco, B., &
Barbosa, C. P. (2011). Genetic aspects of premature ovarian fail-
ure: A literature review. Archives of Gynecology and Obstetrics,
283, 635–643. https://doi.org/10.1007/s00404-010-1815-4
Fimiani, G., Laperuta, C., Falco, G., Ventruto, V., D'Urso, M., Ursini,
M. V., & Miano, M. G. (2006). Heterozygosity mapping by quan-
titative fluorescent PCR reveals an interstitial deletion in Xq26.2‐
q28 associated with ovarian dysfunction. Human Reproduction,
21, 529–535. https://doi.org/10.1093/humrep/dei356
Helle, J. R., Baroy, T., Misceo, D., Braaten, Ø., Fannemel, M., &
Frengen, E. (2013). Hyperphagia, mild developmental delay but
apparently no structural brain anomalies in a boy without SOX3
expression. American Journal of Medical Genetics. Part A, 161A,
1137–1142. https://doi.org/10.1002/ajmg.a.35823
Johnson, B. A., van Diggelen, O. P., Dajnoki, A., & Bodamer, O. A.
(2013). Diagnosing lysosomal storage disorders: Mucopolysaccha-
ridosis type II. Current Protocols in Human Genetics, 79,
17.14.1–17.14.9.
4 | STOOF ET AL.
Jourdy, Y., Chatron, N., Carage, M. L., Fretigny, M., Meunier, S.,
Zawadzki, C.,… Vinciguerra, C. (2016). Study of six patients with
complete F9 deletion characterized by cytogenetic microarray:
Role of the SOX3 gene in intellectual disability. Journal of
Thrombosis and Haemostasis, 14, 1988–1993. https://doi.org/10.
1111/jth.13430
Konkle, B. A., Josephson, N. C., & Nakaya Fletcher, S. (1993).
Hemophilia B.
Li, T., Miller, C. H., Payne, A. B., & Craig Hooper, W. (2013). The
CDC Hemophilia B mutation project mutation list: A new online
resource. Molecular Genetics and Genomic Medicine, 1, 238–245.
https://doi.org/10.1002/mgg3.30
Mercer, C. L., Lachlan, K., Karcanias, A., Affara, N., Huang, S.,
Jacobs, P. A., & Thomas, N. S. (2013). Detailed clinical and
molecular study of 20 females with Xq deletions with special ref-
erence to menstruation and fertility. European Journal of Medical
Genetics, 56, 1–6. https://doi.org/10.1016/j.ejmg.2012.08.012
Moore, S. J., Strain, L., Cole, G. F., Miedzybrodzka, Z., Kelly, K. F.,
& Dean, J. C. (1999). Fragile X syndrome with FMR1 and FMR2
deletion. Journal of Medical Genetics, 36, 565–566.
Nisen, P. D., & Waber, P. G. (1989). Nonrandom X chromosome
DNA methylation patterns in hemophiliac females. Journal of
Clinical Investigation, 83, 1400–1403. https://doi.org/10.1172/
JCI114028
Orstavik, K. H., Scheibel, E., Ingerslev, J., & Schwartz, M. (2000).
Absence of correlation between X chromosome inactivation pat-
tern and plasma concentration of factor VIII and factor IX in carri-
ers of haemophilia A and B. Thrombosis and Haemostasis, 83,
433–437. https://doi.org/10.1038/ng1309
Rizzoti, K., Brunelli, S., Carmignac, D., Thomas, P. Q., Robinson, I.
C., & Lovell-Badge, R. (2004). OX3 is required during the forma-
tion of the hypothalamo‐pituitary axis. Nature Genetics, 36, 247–
255.
Sahoo, T., Theisen, A., Marble, M., Thomas, P. Q., Robinson, I. C.,
& Lovell-Badge, R. (2011). Microdeletion of Xq28 involving the
AFF2 (FMR2) gene in two unrelated males with developmental
delay. American Journal of Medical Genetics. Part A, 155A,
3110–3115. https://doi.org/10.1002/ajmg.a.34345
Sommer, S. S., Scaringe, W. A., & Hill, K. A. (2001). Human germ-
line mutation in the factor IX gene. Mutation Research, 487(1–2),
1–17.
How to cite this article: Stoof SCM, Kersseboom R,
de Vries FAT, Kruip MJHA, Kievit AJA, Leebeek
FWG. Hemophilia B in a female with intellectual
disability caused by a deletion of Xq26.3q28
encompassing the F9. Mol Genet Genomic Med.
2018;00:1–5. https://doi.org/10.1002/mgg3.425
STOOF ET AL. | 5
